Global Peptide Therapeutics Market Projected to Reach $50 Billion by 2030

Global – The global peptide therapeutics market is experiencing rapid growth, driven by increasing demand for metabolic disorder treatments, including obesity and type 2 diabetes. According to a recent report by market research firm Grand View Research, the market is expected to reach USD 50 billion by 2030, with a compound annual growth rate (CAGR) of 8.5%.

GLP-1 receptor agonists, such as Semaglutide and Tirzepatide, have emerged as key drivers of this expansion, revolutionizing weight management and diabetes care. The growing acceptance of peptide-based therapies among healthcare professionals and patients alike is fueling investment in research, manufacturing capacity, and global supply chains.

Industry experts note that China has become a critical hub for peptide API manufacturing, with companies like Zhengzhou Chengque Technology playing an increasingly important role in the global supply network. As demand continues to rise, manufacturers are focusing on quality assurance, regulatory compliance, and supply chain resilience to meet international standards.